Oppenheimer raised the firm’s price target on iRhythm (IRTC) to $225 from $175 and keeps an Outperform rating on the shares. The firm notes Q3 revenue came in at $193M, bucking the seasonal trend and ahead of its/consensus $184M/$185M estimates.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $235 from $220 at Baird
- iRhythm price target raised to $215 from $195 at BTIG
- iRhythm price target raised to $242 from $205 at Citi
- iRhythm price target raised to $212 from $193 at Canaccord
- Irhythm Technologies: Strong Q3 Performance and Positive Outlook Justify Buy Rating